RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
October 08, 2020 10:30 ET | RedHill Biopharma Ltd.
RedHill obtains Israel rights to Movantik® from AstraZeneca, giving RedHill global rights, excluding Europe and Canada--Movantik approved for opioid-induced constipation in Israel under the brand name...
RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik®
August 03, 2020 07:00 ET | RedHill Biopharma Ltd.
RedHill acquired Movantik® for opioid induced constipation from AstraZeneca in April 2020; Movantik® generated $96 million in 2019 --RedHill and Daiichi Sankyo replaced their co-commercialization...